Study Aims to Compare the Use of Systemic Steroids, to the Combination of Systemic Steroids and Methotrexate and to the Combination of Systemic Steroids With Methotrexate and Mycophenolate Mofetil in the Treatment of Idiopathic Granulomatous Mastitis and to Show Response on Subsequent US Examination

November 14, 2026 updated by: Mohannad Fayed, Kasr El Aini Hospital

Comparison of Systemic Steroids, Versus Combined Therapy (Systemic Steroids With Methotrexate) Versus Triple Therapy (Systemic Steroids, Methotrexate and Mycophenolate Mofetil) in the Treatment of Idiopathic Granulomatous Mastitis: Imaging Findings and Clinical Outcomes

The present study aims to compare the use of systemic steroids, to the combination of systemic steroids and methotrexate and to the combination of systemic steroids with methotrexate and mycophenolate mofetil in the treatment of idiopathic granulomatous mastitis. Also, this study aims to show the response to medical treatment on subsequent US examinations.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Cairo Governorate
      • Cairo, Cairo Governorate, Egypt, 11087
        • Recruiting
        • Kasr Al Ainy School of Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Histopathological evidence of IGM.

Exclusion Criteria:

  • Malignancy. Pregnancy Lactation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: one (Monotherapy)

30 female patients with histopathologically confirmed idiopathic granulomatous mastitis

Systemic prednisolone at an initial dose of 30 mg/day

Experimental: two (Double Therapy)

30 female patients with histopathologically confirmed idiopathic granulomatous mastitis

Systemic prednisolone at an initial dose of 30 mg/day

Systemic prednisolone (30 mg/day) combined with oral/subcutaneous methotrexate (25 mg/week) plus folic acid supplementation (10 mg/week).

Experimental: Three (Triple Therapy)

30 female patients with histopathologically confirmed idiopathic granulomatous mastitis

Systemic prednisolone at an initial dose of 30 mg/day

Systemic prednisolone (30 mg/day) combined with oral/subcutaneous methotrexate (25 mg/week) plus folic acid supplementation (10 mg/week).

Systemic prednisolone (30 mg/day), methotrexate (25 mg/week with folic acid), and mycophenolate mofetil (1g/day in divided doses)."

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complete Response
Time Frame: 6 months

Defined as achieving both complete clinical and radiologic remission at 6 months

6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

November 14, 2026

First Submitted That Met QC Criteria

November 14, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 14, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • N-158-2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.